1	Title: Genome-wide DNA methylation-analysis delineates blastic plasmacytoid dendritic
2	cell neoplasm from related entities and identifies distinct molecular features
3	
4	Authors: Axel Künstner ^{1,2,*} , Julian Schwarting ^{2,3,4} *, Hanno M. Witte ^{2,3,5} *, Pengwei Xing ⁶ ,
5	Veronica Bernard ⁴ , Stephanie Stölting ⁴ , Philipp Lohneis ⁴ , Florian Janke ⁷ , Maede Salehi ⁶ ,
6	Xingqi Chen ⁶ , Kathrin Kusch ⁴ , Holger Sültmann ⁷ , Emil Chteinberg ⁸ , Anja Fischer ⁸ , Reiner
7	Siebert ⁸ , Nikolas von Bubnoff ^{2,3} , Hartmut Merz ⁴ , Hauke Busch ^{1,2**} , Alfred C. Feller ^{4**} ,
8	Niklas Gebauer ^{2,3**}
9	
10	Affiliations:
11	¹ Medical Systems Biology Group, University of Lübeck, Ratzeburger Allee 160, 23538
12	Lübeck, Germany
13	² University Cancer Center Schleswig-Holstein, University Hospital of Schleswig-Holstein,
14	Campus Lübeck, 23538 Lübeck, Germany
15	³ Department of Hematology and Oncology, University Hospital of Schleswig-Holstein,
16	Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany
17	⁴ Hämatopathologie Lübeck, Consultation Centre for Lymph Node Pathology and
18	Hematopathology, 23562 Lübeck, Germany.
19	⁵ Department of Hematology and Oncology, Federal Armed Forces Hospital Ulm, Oberer
20	Eselsberg 40, 89081 Ulm.
21	⁶ Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala,
22	Sweden.
23	⁷ Division of Cancer Genome Research, German Cancer Research Center (DKFZ), 69120
24	Heidelberg, Germany; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.
25	⁸ Institute of Human Genetics Ulm University and Ulm University Medical Center, 89081
26	Ulm, Germany.

27 Scientific category: Myeloid Neoplasia

- 28 Running Title: BPDCN methylome
- 29 Key Words: blastic plasmacytoid dendritic cell neoplasm, whole-exome sequencing, RNA-
- 30 sequencing, methylome, AML
- 31 Word Count (Text): 6569 (incl. Materials and Methods)
- 32 Word Count (Abstract): 150
- 33 References: 76
- 34 **Tables: 1**
- 35 Figures: 6
- 36 Supplementary Tables: 5
- 37 Supplemental Figures: 7
- 38 **Competing Interests:** The authors declare no conflicts of interest.
- 39
- 40 *These authors contributed equally to this manuscript
- 41 **Shared senior authorship
- 42 **Date of submission: 27.07.2023**
- 43 Corresponding Author:
- 44 PD Dr. med. Niklas Gebauer
- 45 Department of Hematology and Oncology
- 46 UKSH Campus Luebeck
- 47 Ratzeburger Allee 160
- 48 23538 Luebeck
- 49 Email: <u>Niklas.Gebauer@uksh.de</u>
- 50
- 51
- 52

53 Abstract:

54 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) constitutes a rare and aggressive 55 malignancy originating from plasmacytoid/common dendritic cells (pDCs/cDCs) with a 56 primarily cutaneous tropism followed by dissemination to the bone marrow and other organs. 57 We conducted a genome-wide analysis of the tumor methylome in an extended cohort of 45 58 BPDCN patients supplemented by WES (n=54) and RNA-seq (n=54) as well as ATAC-seq 59 on selected cases (n=4). We determine the BPDCN DNA methylation profile and thereby 60 identify a reliable means to discriminate BPDCN from AML, CMML and T-ALL. DNA 61 methylation profiling characterizes disruption of oncogenic pathways whilst unraveling the 62 proliferative history as well as the prognostically relevant composition of the tumor 63 microenvironment. Beyond the two recently established BPDCN subtypes (C1/C2), we 64 identified a transcriptional reliance on JAK/STAT and NFkB-signaling in atypical C2 versus 65 C1-BPDCN cases through RNA-sequencing. Our integrative characterization of BPDCN 66 offers novel molecular insights and potential diagnostic applications.

67

68 Introduction:

69 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and extremely rare 70 blood cancer, accounting for approx. 0.5% of acute hematological malignancies. In its recent 71 editions, the WHO classification of myeloid neoplasms recognizes BPDCN as a distinct entity descending from non-activated, CD56⁺ plasmacytoid dendritic cells (pDC)^{1, 2, 3}. However, a 72 73 broader cellular origin encompassing transcriptional signatures of both AXL1⁺ SIGLEC6⁺ 74 DCs and earlier, common dendritic cells, termed AS-DCs and cDCs, respectively, has been proposed, before, suggesting a diverse cellular ontogeny 4, 5, 6. Clinically, skin lesions 75 76 commonly precede bone marrow infiltration and secondary propagation into lymph nodes and 77 extranodal organs. A striking 4:1 male predominance, attributed to sex-biased ZRSR2 78 mutations and enrichment in elderly patients with a median age of around 70 years at

diagnosis has been observed ^{7, 8}. While the typical BPDCN immunophenotype (CD4⁺, CD56⁺, 79 80 CD123⁺) is relatively specific and reliably enables correct diagnosis, discrimination from AML, especially cases with pDC features can be challenging ^{9, 10}. Investigation of pDC-81 82 associated antigens (e.g., TCL1 or CD303) can further facilitate differential diagnosis, while 83 the expression of B- (CD79b), T- (CD2, CD7) and precursor antigens (Tdt) poses variable 84 pitfalls¹¹. Treatment with conventional chemotherapy alone results in insufficient and short-85 lived remissions (median overall survival (OS) of 12 to 14 months), which necessitates either 86 allogeneic or autologous stem cell transplantation (SCT) in therapeutic approaches of curative intent ^{7, 12, 13}. Only through the introduction of tagraxofusp, a CD123-directed cytotoxin, 87 88 which recently demonstrated high clinical efficacy, curative treatment has become possible in elderly patients, as well, while the outcome in relapsed/refractory cases remains dismal¹⁴. 89 90 Genome-wide DNA methylation profiling has evolved from a descriptive, ontological 91 analysis into a diagnostic assay of prognostic relevance across a variety of solid cancers, including CNS tumors and sarcomas^{15, 16}. While genomic and transcriptional profiling has 92 93 revolutionized the taxonomy of myeloid cancers, embedded in the current WHO 94 classification, the study of DNA methylation may add another layer of insight into BPDCN 95 biology that is so far insufficiently captured by DNA- and RNA-sequencing¹. Methylome 96 analysis may further assist in differential diagnostics between BPDCN and other malignancies 97 sharing close molecular ties including chronic myelomonocytic leukemia (CMML), acute 98 myeloid leukemia (AML) and myelodysplastic syndromes (MDS), which may occur syn- and

99 metachronously in up to 20% of cases 17 .

DNA methylation profiling can further assess the tumor immune microenvironment (TME), by deconvoluting cell types from within tissue-derived bulk DNA and discriminating immunologically hot from cold tumors ¹⁸. The robust correlation of its output with an immunohistochemical dissection of the TME has been shown in non-small cell lung cancer and others ^{18, 19}.

In this study, we have extended our previously published BPDCN cohort⁶, assessed by paired whole-exome (WES) and RNA-sequencing (RNA-seq) as well as genome-wide copy number analysis and conducted array-based genome-wide DNA methylation profiling and ATACsequencing on selected cases, allowing for a more profound and novel understanding of BPDCN pathobiology and reliable discrimination from AML as the predominant diagnostic challenge in clinical practice. Moreover, we identify two immunological subtypes, characterized by features in the TME and recurrent genomic alterations.

112

113 **Results**

114 Clinical characteristics of the study group and expanded deconvolution cohort

115 We collected 54 quality controlled (diagnostic BPDCN samples with sufficient formalin-fixed 116 paraffin-embedded (FFPE) tissues (age range 15 - 91 years; mean/median 69/72 years). We 117 observed an expectedly strong male predominance (40/54; 74%) and uniform cutaneous 118 involvement alongside a pronounced proclivity for extranodal involvement. Of patients in 119 first complete (CR) or partial remission (PR), 24% went on to autologous/allogeneic SCT. 120 Clinical outcomes, when available, reflected previous dismal observations in BPDCN with a 121 median progression-free and overall survival of eight and twelve months, respectively. Best 122 supportive care was provided in four cases where any form of anti-neoplastic treatment was 123 refused.

BPDCN-specific markers were expressed in all cases, whereas precursor antigens (CD34, TdT) were present in 5/47 (11%) and 34/47 (72%) respectively. Baseline clinicopathological characteristics of BPDCN cases included in the current study are briefly summarized in **Table** 1. In accordance with our previous study, RNA-seq data were deconvoluted according to single-cell DC and monocyte datasets and previous observations were recapitulated/extended to new samples including differentially mutated genes (**Supplementary Figures 1 and 2**).

130	Additionally, mutational landscape and MutSigCV analysis were extended to new cases as
131	previously described (Supplementary Tables 1 and 2) ⁶ . Tumor mutational burden (TMB)
132	was confirmed to be significantly higher ($p = 0.0055$) among C1-BPDCN and an updated set
133	of differentially mutated genes was identified (Supplementary Figures 3a and 3b).
13/	

134

135 Epigenetic profiling reveals significant deregulation of key regulatory pathways through

136 loss of DNA methylation compared to dendritic cells

137 In order to assess epigenetic processes contributing to the malignant transformation from DCs 138 to BPDCN and to allocate the entity within the spectrum of blood cells, we performed a 139 principal component analysis (PCA) of BPDCN and various cell types of the peripheral blood (Figure 1)²⁰. Expectedly, we observed a clear segregation of blood cell types and BPDCN, 140 141 but beyond this, a marked difference between BPDCN and previously profiled DC subsets became apparent (Figure 1a)²¹. This was further reflected in significantly higher global mean 142 143 DNA methylation levels in both early and more mature DCs, signifying the dramatic extent of 144 DNA methylation loss during malignant transformation of DCs towards BPDCN (Figure 1b). 145 An enrichment analysis of differentially methylated regions (CpG FDRs < 0.01, absolute 146 difference above 0.3, enrichment analysis against HALLMARK and REACTOME gene sets) 147 revealed significantly reduced DNA methylation in candidate genes involved in processes like 148 extracellular matrix organization, collagen modulation and the neuronal system as recently 149 implicated in BPDCN pathobiology²². Moreover, potentially oncogenic driver processes 150 affected by these altered profiles included KRAS signaling and the interaction with the 151 extracellular matrix (Figure 1c, d).

152

BPDCN is characterized by a DNA methylation profile distinct from its related entities
yet borderline cases exist.

155 To assess the potential of DNA methylation analysis in the differential diagnosis between 156 BPDCN and AML as well as CMML, we performed a comparative analysis of DNA 157 methylation data between our cohort and a previously published cohort of AML patients, 158 representing all relevant molecular subtypes, reanalyzing the BEAT-AML cohort as well as a 159 CMML cohort previously published by Palomo et al. This analysis revealed a separation of 160 samples into entity-specific DNA methylation classes in both an unsupervised (PCA; Figure 161 **2a**) as well as a supervised (PLS-DA; Figure 2b) approach. Distinction from T-cell acute 162 lymphoblastic leukemia (T-ALL) and malignant melanoma, which was added for comparison, 163 as another entity originating in the skin, driven by a UV-related mutational signature, was 164 even more pronounced (Figure 2j). Intriguingly, we observed four borderline cases through 165 our DNA methylation-based classification (Figure 2c; BPDCN_01; 15; 27; 37), exhibiting a 166 relevant amount of overlap between both groups in terms of DNA methylation. In contrast to 167 the overall clear distinction between BPDCN and AML, we found three of these cases to 168 exhibit synchronous concurrent manifestations of AML and/or transformed CMML with pDC 169 features and one of these three cases even presented with genetic features typically 170 encountered in AML with pDC-features (e.g., a *RUNX1* mutation; Figure 2c, d-i). The one 171 patient allocated closest to the 95% CI cut-off for the AML definition by our analysis, 172 exhibited a typical pDC-like C1-BPDCN phenotype, while the other, more pronounced 173 borderline classified cases were C2 cases, exhibiting a more immature DC phenotype with 174 fractional monocyte signatures. Subsequent comparative pathway enrichment analysis against 175 HALLMARK and REACTOME gene sets for most differentially methylated regions (DMRs) 176 within gene-body regions revealed a significant enrichment across RHO GTPases, cell 177 migration control and leukemic stem cell maintenance (via HSF1 activation) in BPDCN, 178 whereas promotor regions in BPDCN compared to AML were methylated to a significantly 179 higher degree in epigenetic and transcriptional regulation as well as TP53 regulation and cell 180 cycle control. (Figure 2m-o).

181

The BPDCN genome is characterized by an exceptional degree of DNA methylation loss and epigenetic signs of mitotic stress

184 Global DNA methylation is commonly diminished in malignant compared to healthy cells, 185 being stably maintained in the latter. In this line, BPDCN revealed even the highest methylation loss compared to other blood cancers, including AML, CMML, and T-ALL^{23, 24,} 186 187 ²⁵. Global methylation levels in BPDCN even fall below that of melanoma, irrespective of the 188 C1 or C2 subtype (Wilcoxon rank-sum test, p < 0.001). Melanoma was chosen for 189 comparison because of its origin from UV-light exposure in the skin and the ensuing overlap in the mutational signatures (**Figure 2k**)^{8, 26}; transcriptional BPDCN subtype (C1 vs C2) did 190 191 not affect this. Intriguingly, the aggressive clinical nature of BPDCN was further reflected in 192 our observations made through the application of epiCMIT, a DNA methylation-based mitotic clock, which recapitulates the proliferative history of a given tumor sample ²⁷. epiCMIT 193 194 predicted a significantly accelerated mitotic history in BPDCN compared to CMML and even 195 AML, matched only by T-ALL (Figure 21). Although an independent prognostic impact of a 196 high epiCMIT score was observed for a wide range of blood cancers, we observed no such 197 trend in our cohort, plausibly attributable to the limited sample size.

198

DNA methylation of tumor suppressor genes is highly deregulated in BPDCN compared to CMML and AML.

In keeping with a substantially deregulated DNA methylation profile in BPDCN and a global loss of DNA methylation, we observed promotor regions of tumor suppressor genes to be methylated to an exceptionally high degree, compared to CMML and even AML (**Figure 3a**). At the same time a significantly lower level of gene-body associated methylation in the same

205 genes was identified, again in comparison with CMML and even AML (Figure 3b), 206 indicating a substantial oncogenic impact of deregulated DNA methylation in BPDCN 207 (manually selected candidate TSGs, Figure 3c, for exhaustive information on deregulated 208 TSGs see Supplementary Figure 2). Strikingly, we hereby observe an increasingly 209 deregulated DNA methylation profile from CMML to BPDCN in parallel to the 210 aggressiveness of the entity's clinical behavior, ranging from the rather indolent and slowly 211 progressing course of CMML in comparison to the more aggressive clinical presentation of 212 AML, which is even more pronounced in BPDCN.

213

214 Differential DNA methylation patterns and gene expression signatures differentiate C1

and C2 subtypes in BPDCN and shape a JAK/STAT-driven profile in C2-BPDCN

Building on our previous BPDCN subtype classification, we performed a differential DNA methylation analysis. Alongside differentially mutated genes in BPDCN, we discovered 114 probes, which were differentially methylated between C1 and C2 (p < 0.0001; 10,136 probes with p < 0.01), corresponding to a relatively similar methylome, in keeping with our above PCA/PLS-DA (depicted as scales beta values in **Figure 4a**; beta values see **Supplementary Table 4**).

Subsequently, to gain insight into the effect of differential DNA methylation on the phenotypical development of both subtypes, we assigned differentially methylated probes to their respective genes (**Figure 4b**). Gene set testing (GST) (**Figure 4c**) revealed enrichment in elevated DNA methylation levels for interleukin signaling genes as well as prominent members of JAK/STAT signaling (including STAT5B) in C1-BPDCN, whereas C2-BPDCN samples exhibit significantly pronounced DNA methylation of posttranslational modifications like glycosylation and metabolic processes (e.g., vitamin and heme metabolism).

229 Expanding on our differential assessment of C1 and C2-BPDCN onto the transcriptional 230 level, we performed differential gene expression analysis (Figure 4d, e). Hereby, we 231 observed an induction of innate and adaptive immunological processes alongside an 232 upregulation of extracellular matrix-interactions in C2 cases by gene set enrichment. Further, 233 we found several prominent candidate genes, including STAT5A, CDK6, CCR4, CCND2 and 234 FOXO1 to be expressed at significantly higher levels in atypical C2 cases. Corresponding to higher gene expressions in C2, CDK6 (p = 5.3×10^{-4} , log₂ fold-change 1.52) and STAT5A (p = 235 5.5×10^{-3} , log₂ fold-change 1.19) had promotor-associated sites that were significantly higher 236 237 methylated in C1-BPDCN leading to relative transcriptional inactivation in C1. Correlation of 238 DNA methylation and relative RNA-seq derived gene expression data yielded a substantial 239 number of significant correlations among TSGs and oncogenes including BCL2, STAT5A and 240 SOX1 (Supplementary Table 5a). Upon extension of the analysis unto the entire 241 transcriptome further significant correlations (q < 0.1) were observed (**Supplementary Table** 242 5b).

243 In order to further focus our observations on potential therapeutic applicability, we inferred 244 transcription factor (TF) activities from bulk RNA-seq data employing CollecTRI as a 245 resource for TFi pathway activity inference with PROGENy. Hereby we observed the 246 transcriptional mirror image of the divergence in DNA methylation profiles between C1 and 247 C2-BPDCN. In particular, we observed significantly higher activity of NFkB (driven by 248 FOXC1, NFKB1 and NFKB; p < 0.05) and more strikingly JAK-STAT (predominantly 249 driven by STAT3, STAT1 and STAT5A; p < 0.05) associated TF in C2 and an EZH2 250 dependence in C1-BPDCN (Figure 4f, g). In addition, we supplemented these observations 251 by FFPE-ATAC-seq of four C2-BPDCN, which revealed substantial chromatin accessibility, 252 in keeping with our epigenetic and transcriptional findings (Figure 4h, i).

254 Cellular composition of the tumor microenvironment by MethylCIBERSORT and 255 immunohistochemistry reveals distinct immunological subtypes correlated with tumor 256 genomics

257 In order to evaluate the composition of the tumor microenvironment (TME), we conducted a 258 MethylCIBERSORT analysis on all 45 high-quality genome-wide DNA methylation profiles 259 from primary diagnostic samples. From the inferred relative abundance of T cells and their 260 respective subpopulations (CD4⁺ effector cells, CD8⁺ cytotoxic cells, regulatory T cells 261 (Tregs)) alongside B-cells, natural killer (NK)-cells neutrophils, monocytes, eosinophils and 262 stromal cells (fibroblasts, endothelial cells) two TME classes (IC1 and IC2) were predicted. 263 The smaller class (IC1) exhibited a depletion in monocytes, B- and NK-cells, an enrichment 264 in Tregs and a trend towards higher counts of neutrophils and cytotoxic T cells (Figure 5a). 265 These observations were subsequently validated via IHC for tumor-infiltrating T cells and 266 monocytes with a significant correlation between relative distributions of cell populations 267 according to the respective methodology (Figure 5b - e, g, h). Comparing IHC and 268 MethylCibersort estimates, we found a significant correlation in monocytes (Pearson correlation coefficient = 0.6437, p = 1.84×10^{-6}) and in T-cell populations (Pearson correlation 269 270 coefficient = 0.3809 p = 0.0098). Beyond a statistical trend towards an overall higher TMB, 271 we observed an enrichment in mutations affecting ERBB2, ASXL1, EP300 and KMT2C 272 mutations. Further, we identified more frequent mutations in CDH1, JAK2, SMAD2, 273 *NOTCH1* and *DNMT3A* (Figure 5 f). Patients in the IC1 subgroup had a significantly shorter 274 progression-free survival (p = 0.039) and a trend towards inferior overall survival (p = 0.14) 275 in IC1 patients (Figure 5 i, j). Correlating the results from our MethylCIBERSORT approach 276 with the genomic landscape of BPDCN (restricted to on genes mutated in at least 30% of 277 cases; n = 8), mutations in *EP300*, *KMT2C* and *NOTCH2* were associated with a significant 278 enrichment of eosinophils (*KMT2C*: p = 0.038), monocytes (*EP300*: p = 0.045; *NOTCH2*: p = 0.045; *NOTCH2*; *NOTCH2*; *NOTCH2*; *NOTCH2*; *NOTCH2*; *NO*

279 0.0026), CD4 effector cells (*EP300*: p = 0.042) and regulatory T-cells (*EP300*: p = 0.012) 280 within the TME, respectively (Supplementary Figure 4). Previous reports identified a strong correlation between DNA methylation and chronological age ^{28, 29}. Based on our 281 282 MethylCIBERSORT results leading to the allocation of two clusters, epiCMIT was applied to 283 proliferative estimate the history of stress/DNAm age. In contrast to the 284 genome/transcriptome-based BPDCN clusters C1/C2 (Figure 2l), the immunological cluster 285 IC2 showed a DNA methylation imprint of significantly higher proliferative stress compared 286 to IC1, which resembles DNA methylation-based pre-aging in this subgroup (p = 0.038; 287 Supplementary Figure 5).

In keeping with the higher levels of DNA methylation and the subsequently suppressed expression of adaptive immunological processes in typical pDC-like C1-BPDCN cases, we observed a trend towards higher levels of tumor-infiltrating T-cells in C2-BPDCN samples despite the overall higher TMB in C1 patients, regardless of patient age or location of the tumor sample by both MethylCIBERSORT and IHC (**Supplementary Figure 6a, b**).

293

DNA methylation-based clusters cannot be fully recapitulated in transcriptional BPDCN subtypes

The most 5,600 variable CpG probes were subject to discovering DNA methylation subtypes using K-means clustering. The optimal number of clusters was determined using the average silhouette method and gap statistics. Both methods agreed on the optimal number of clusters (n = 2). Upon unsupervised cluster analysis, we observed no statistically significant recapitulation of transcriptional BPDCN subtypes C1 and C2 in the methylome. Some overlap was, however, found in shared genomic features (*EP300* and *ATRX* mutations in C1 and MethC1), consistent with higher TMB in C1 and MethC1. A significantly more pronounced

303 overlap was apparent upon correlation analysis between DNA methylation-based cluster
304 allocation and immunological clusters according to our methyCIBERSORT-derived
305 immunoclusters (Supplementary Figure 7a,b).

306

307 Mutational drivers and promotor status of epigenetic regulators shape the proliferative

308 fate and DNA methylation profile of BPDCN

309 In order to provide a genomic context for the DNA methylation profiles obtained within this 310 study, we performed WES on all patients, who were not part of our previous molecular 311 landscape project in BPDCN, which led to the most comprehensive mutational 312 characterization of any BPDCN cohort to date (Figure 6a). WES of our extended BPDCN 313 cohort identified a higher mutational load compared to the C2 cluster. This further supports 314 the assumption of another non-mutational mechanism driving in C2-BPDCN such as a 315 deregulated DNA methylation and transcriptional profile outlined above. The exceptional 316 pathophysiological role of epigenetic features within the C2 cluster is supported by more 317 frequent DNMT3A alterations bordering on statistical significance in this limited cohort and 318 the significant deregulation of splicing genes such as SRSF2.

319 Following mutational characterization, we wondered whether specific mutational drivers were 320 associated with the proliferative history of a given case, thereby integrating mutational and 321 epigenetic datasets in order to identify genetic alterations, which could confer a selective 322 advantage as mitotic accelerators in BPDCN cells. While definitive conclusions are 323 complicated by the limited sample size, we observed a trend towards a proliferative increase 324 in cases harboring ARID1A, ZRSR2, JAK3, CIC and CREBBP mutations and a (significant) 325 decrease in mitotic activity in cases affected by mutations in PPARGCIA, CDH1, SI, RUNX1, 326 SF3B1, MSH2 and SETD2 (Figure 6b, c). In summary, our findings suggest, that the

327 proliferative potential of BPDCN is determined by certain mutational driver events.

328	In order to unravel additional determinants, which shape the overall strongly demethylated
329	landscape in BPDCN, we investigated the promotor DNA methylation status of a set of genes
330	associated with epigenetic regulation (Figure 6d). Hypermethylation of the promotor region
331	(promoter CGI methylation >0.2) of DNMT1, WT1, MYC and TET1 was hereby observed in
332	42.2%, 73.2%, 40.0% and 53.3% of patients respectively. Further, we observed a significant
333	correlation between promotor methylation and overall CGI methylation for 22 of the 24 genes
334	(Spearman's rank correlation, $p_{adj} < 0.05$) signifying a substantial impact on the epigenetic
335	landscape in BPDCN. Only DNMT1 and KMD2B did not show a significant correlation. Of
336	note, a substantial overlap between patients harboring WT1 and MYC promoter methylation
337	was observed 16/45 cases (35.6%). Given that MYC constitutes a known WT1 target, this
338	hints at a coupled mechanism of both genes in BPDCN pathogenesis 30 (Figure 6b, c).

339

340 **Discussion**

341 BPDCN is a clinically and molecularly heterogeneous disease that poses a multi-level 342 challenge in terms of diagnostics and treatment alike. Unraveling the epigenetic 343 characteristics of the disease may pose an aid in providing a correct and timely diagnosis, 344 which is crucial for the initiation of specific treatments. Through a comparative analysis of 345 the DNA methylation landscape of BPDCN incorporating related hematological malignancies 346 (AML, CMML and T-ALL patients, encompassing all relevant genetic and phenotypical 347 subgroups), we identify distinguishing features and provide unprecedented insights into the 348 molecular pathogenesis of BPDCN, which may in term facilitate the development of more 349 refined targeted therapeutic approaches. In this integrated molecular study of BPDCN we 350 report on the largest cohort studied so far. Where previous reports on BPDCN were limited by

small cohorts and restricted methodological approaches, we systematically defined genomic
 and transcriptional signatures in the context of genome-wide DNA methylation ^{4, 8, 10, 31, 32, 33,}
 ^{34, 35, 36, 37}. Hereby, we made three novel and essential observations.

354 First, our study of DNA methylation profiles allowed for a clear distinction between globally 355 demethylated BPDCN patient samples with only localized DNA hypermethylation showing 356 dominant signs of mitotic stress, resembling a pronounced variant of the canonical cancer 357 methylome on the one hand and AML, CMML as well as T-ALL on the other. In keeping 358 with previous assumptions, we find enrichment in cases with distinct DNA hypomethylation, 359 predominantly affecting late-replicating regions and molecular signs of extensive past mitotic stress ³⁸. Several patients, for whom a borderline DNA methylation profile between AML and 360 361 BPDCN was identified, were found to resemble cases with either syn- or metachronous 362 development of CMML/AML or a molecular and phenotypical constellation resembling AML with pDC-like features ^{9, 10}. Moreover, we observed all but one of these cases to exhibit the 363 atypical, more immature cDC-impacted C2-BPDCN transcriptional profile ⁶. This aligns with 364 365 observations in B-cell malignancies and solid tumors where the DNA methylation profile reflects the degree of maturation of the cell-of-origin ^{27, 39}. Recently, clonal hematopoiesis of 366 367 indeterminant potential (CHiP), disrupting epigenetic regulators in the majority of BPDCN 368 cases, was proposed as an underlying mechanism rendering secondary mutations in RAS 369 signaling (NRAS, KRAS) and tumor suppressors like TP53 and ATM secondary clonal events 370 and thereby more specific in BPDCN pathogenesis ⁴⁰. Our previous genomic studies revealed 371 a significant overlap in mutational drivers between BPDCN and the abovementioned entities, 372 underscoring the close molecular relatedness between BPDCN and especially AML/CMML, 373 which was recently further illustrated in cases of divergent clonal evolution from a CHiP 374 constellation. The present study of DNA methylation signatures, however, revealed a 375 significant impact on signaling processes ultimately contributing to the specific phenotype of

376 BPDCN in particular. This can therefore be harnessed as a reliable discriminator beyond established immunophenotypical and histopathological approaches ^{23, 41, 42}. Moreover, DNA 377 378 methylation profiling revealed a canonical epigenetic deregulation of TSGs with putative oncogenic effects, vastly exceeding previous observations in related entities ^{23, 24}. 379 380 Intriguingly, we observed several mutational drivers of mitotic stress, signified through a 381 proliferative epigenetic signature. In line with previously reported effects of ARID1A 382 mutations on cell proliferation, we found ARIDIA mutant BPDCN samples to exhibit 383 pronounced signs of proliferative activity, while decreased mitotic activity in *RUNX1* mutant 384 BPDCN is in keeping with reduced proliferation in hematopoietic stem cells harboring similar mutations ^{43, 44}. At the same time, unsupervised clustering of genome-wide DNA methylation 385 386 levels only partially recapitulated transcriptional clusters, which was, however, previously 387 observed in other blood cancers (e.g., T-ALL) as well⁴⁵.

388 Second, our recently established molecular subgroups of BPDCN differ in terms of both 389 transcriptional profile by RNA-seq and to a lesser extent by DNA methylation signature. 390 Confirming and expanding on previous studies, we found predominant pathways deregulated 391 by these circumstances to include both innate and adaptive immunological processes, for 392 which gene expression was significantly induced in C2-BPDCN cases. This corresponds well 393 to elevated DNA methylation levels in interleukin/inflammatory signaling genes in C1-394 BPDCN, leading to a relative up-regulation of the interleukin 4/13 interactome in C2-BPDCN 395 ⁴⁶. Interrogating our bulk RNA-seq data for TF activity, we observed the transcriptional 396 mirror image of the divergence in DNA methylation profiles between C1 and C2-BPDCN. Of 397 particular interest, regarding potential therapeutically targetable vulnerabilities, we observed 398 significantly higher activity of NFkB (driven by FOXC1, NFKB1 and NFKB) and more 399 strikingly, JAK-STAT (predominantly driven by STAT3, STAT1 and STAT5A) associated TF 400 activity in C2 in contrast to an EZH2 dependence in C1-BPDCN. Potent and clinically well-401 tested inhibitors for potential molecularly informed therapeutic combinations with

402 tagraxofusp are readily available 47 . These observations were then verified by FFPE-ATAC-403 seq, which revealed substantial chromatin accessibility at highly expressed loci, including 404 *CDK6* and *STAT5A*, in keeping with our epigenetic and transcriptional findings.

405 Finally, we gained insight into the tumor immune microenvironment through the combined 406 analysis of MethylCIBERSORT and immunohistochemistry. The essential finding was that 407 there are two, prognostically relevant immunologic clusters (IC1 and IC2) in BPDCN, 408 characterizing the unfavorable IC1 subgroup (comprising approx. 25% of patients) harboring 409 a trend towards a higher TMB and significant enrichment for ERBB2, ASXL1, EP300 and 410 *KMT2C* mutations alongside a TME relatively depleted of NK-cells, monocytes and B-cells 411 but enriched in Tregs. A previous report raised the issue of immunotherapeutic approaches in levels⁴⁸. 412 BPDCN immunohistochemically investigating PD-L1 expression Our 413 comprehensive MethylCIBERSORT approach identified a relevant subset of immunologic 414 hot cases in which immunotherapeutic strategies seem to be promising in light of lacking treatment options beyond tagraxofusp⁴⁸. Moreover, we found that IC2 had a significantly 415 416 higher epigentic age but there was no difference regarding chronological age between both subgroups. This is congruent with previous observations in NSCLC¹⁹, where it was 417 418 hypothesized that a higher epigentic age was able to emulate the malignant potential of 419 tumors with a high mutational load or decisive driver mutations such as TP53. However, the 420 authors went on to demonstrate that a higher epigentic age was associated with favorable 421 survival compared to tumors characterized by genomic instability and high mutational loads¹⁹. In addition to the immunologically defined clusters, we observed an elevated level of 422 423 TILs in atypical C2-BPDCN. Our future goal is now to dissect the TME in even greater detail 424 by single-cell RNA sequencing and spatial transcriptomics.

425 Limitations of the current study include a restricted number of cases alongside a partial lack426 of information on clinical follow-up for about half of the cohort. Additionally, a substantial

427 subset of tagraxofusp-treated patients will make a valuable addition to future studies.

428	In conclusion, employing an integrated molecular approach, we are able to reliably						
429	distinguish BPDCN from its related entities and identify clinical and molecular borderline						
430	cases. Further, we unravel the epigenetic and transcriptional underpinnings of our two						
431	recently defined subtypes of BPDCN, identifying divergent potential targetable vulnerabilities						
432	and characterizing immunologically and prognostically meaningful subtypes through DNA						
433	methylation profiling-derived quantitative TME assessment validated by						
434	immunohistochemistry.						

435

.....

436 Methods

437 Case selection, clinicopathological assessment, whole exome, and whole transcriptome 438 sequencing

439 For this retrospective analysis, we reviewed our institutional archive for cases of 440 histologically confirmed BPDCN between January 2001 and April 2022. The study was 441 approved by the ethics committee of the University of Lübeck (reference-no 18-311) and 442 conducted in accordance with the declaration of Helsinki. Patients at the Consultation Center 443 for Hematopathology provided written informed consent regarding routine diagnostic and 444 academic assessment, including genomic studies. Histopathological work-up was performed 445 as described⁶ and yielded 74 cases of BPDCN, 54 of which had sufficient FFPE tissue 446 samples available for subsequent molecular analysis were selected and subjected to a 447 comprehensive immunophenotypic workup (47 samples were included in a previously 448 published investigation of the mutational landscape in BPDCN⁶). Genomic DNA and RNA 449 were extracted from three 5µm FFPE tissue sections of either tumor or normal tissue (where 450 available; n = 3) employing Maxwell® RSC DNA FFPE kit and Maxwell® RSC RNA FFPE 451 kit (both Promega). WES and RNA-Seq following library preparation using Agilent

452	SureSelect Human All Exon V6 library preparation kit (Agilent Technologies) and
453	NEBNext® UltraT Directional RNA Library Prep Kit (New England BioLabs), respectively
454	were performed on a NovaSeq platform (Illumina) at Novogene (UK) Co. as described ⁴⁹ .
455	Tumor whole exome libraries were sequenced to a median depth of $131x$ (mean 134 ± 52 s.d.)
456	and normal libraries reached a median depth of $67x$ (mean 83 ± 36 s.d.).

457

458 Whole exome data processing and variant calling

459 Sequencing data from WES was processed using the same workflow as previously described ⁶. Briefly, raw reads (paired-end fastq format) were trimmed (adapter and quality values) 460 461 applying FASTP (v0.23.0; minimum length, 50 bp; maximum unqualified bases, 30%; trim tail set to 1)⁵⁰; trimmed reads were mapped to GRCh38 using bwa mem $(v0.7.15)^{51}$ and mappings 462 463 were converted into BAM format using PICARD TOOLS (v2.18.4). Next, mate-pair information 464 was fixed, PCR duplicates were removed, and base quality recalibration was performed using PICARD TOOLS, GATK (v4.2.3.0)⁵² and dbSNP v138⁵³. Single nucleotide variants (SNVs) 465 466 and short insertions and deletions (indels) were identified following GATKs best practices for 467 somatic mutation calling (matched normal-tumor mode for samples with normal tissue 468 available (n=3) and tumor-only mode for samples without normal tissue available). MUTECT2 (GATK)⁵⁴ was applied to the processed mappings with GNOMAD variants as germline 469 470 resource and the b38 exome panel from the 1000 genome project as a panel of normal, 471 capturing the expected repertoire of germline variants to be expected in a Central European 472 study population. Next, FFPE read orientation artifacts were identified and removed 473 according to GATK guidelines. Filtered variants were annotated using VARIANT EFFECT PREDICTOR⁵⁵ (VEP v103, GRCh38; adding CADD v1.6, dbNSFP v4.1a23, and GNOMAD 474 475 r3.0 as additional resources) and annotations were converted into MAF format using VCF2MAF 476 (V1.6.21) (DOI:10.5281/ZENODO.593251); coverage was extracted directly from the vcf INFO field. The top 20 frequently mutated genes (FLAGS)⁵⁶ were removed from further 477

478 analysis and the remaining somatic variants were filtered as follows: minimum coverage of 479 40, minimum alternative allele coverage of 5, minimum variant allele frequency of 10%, and 480 only variants with a frequency < 0.1% in 1000 genomes, GNOMAD, or ExAC were 481 considered for subsequent downstream analysis. High-impact variants (CADD score > 10) in tumor suppressors according to Vogelstein et al. 57 were filtered as such that minimum 482 483 coverage of 20 minimum, minimum alternative coverage, and minimum variant allele 484 frequency of 10% was required. Genes mutated more often than expected were identified by applying MUTSIGCV $(v1.41)^{58}$ and potential drivers were identified using p < 0.001. Tumor 485 486 mutational burden (TMB) did not differ between tumor-only samples and samples with 487 matched normal tissue at the finalization of the filtering process (Wilcox test, p = 0.1004).

488

489 Transcriptome Data Processing, Quantification, Deconvolution, and Analysis

490 Gene expression sequencing data were processed in the same manner as described previously 491 ⁶. Briefly, gene expression profiles were retrieved from adapter trimmed reads (FASTP as described above) using STAR ALIGNER (v2.7.4b)⁵⁹ against GRCh38 (GENCODE v37) as 492 493 reference. On average 73.5 million reads (median 81.1) were successfully mapped to the 494 human reference per tumor sample and 29.6 million reads (median 30.4) per normal sample, 495 respectively. Count profiles were normalized applying MIXNORM (v0.0.0.9000; 50 iterations, tolerance set to 0.1)⁶⁰, which removes unwanted biological and technical effects 496 497 from FFPE material that can bias the signal of interest. Differentially expressed genes on 498 normalized expression values between two conditions were identified using a linear modeling approach (LIMMA package, v3.50.1)⁶¹. 499

500 Pathway enrichment analysis against REACTOME gene sets (MSIGDF R package v7.4) on 501 significantly differentially expressed genes was performed using a rank-MANOVA-based 502 approach as implemented in MITCH (v1.12.0; priority on significance) ⁶²; NF- $\kappa\beta$ pathway 503 (KEGG) was added manually to the REACTOME gene set.

504 Previously published scRNA-data from Villani et al.⁶³ was used to infer the cell-type 505 composition of the bulk RNA-Seq data with respect to dendritic cells and monocytes applying

⁵⁰⁶ a deconvolution of damped weighted least squares (DWLS) method as described previously ⁶.

507 Transcription factor and Pathway activities from RNA-seq data

Transcription factor activities were inferred from RNA-seq data using prior knowledge as provided by Collection of Transcriptional Regulatory Interactions (CollecTRI (Preprint at https://doi.org/10.1101/2023.03.30.534849 (2023)), DECOUPLER v2.6.0), which provide a curated collection of 1,175 transcription factors. Briefly, t-values between two conditions (BPDCN DC cluster) were estimated using LIMMA. Transcription factor activities were estimated on *t*-values using weighted means and activities with p < 0.05 were plotted (28 transcription factors).

515 Pathway activities for curated pathways with weights for each interaction were estimated 516 using Pathway RespOnsive GENes for activity inference (PROGENy 64 , gene signatures for 517 14 pathways) on limma estimated *t*-values (as above).

518

519 Genome-wide DNA methylation profiling and data analysis

520 Whole-genome DNA methylation analysis was carried out on all 54 cases of the study cohort 521 employing the Illumina EPIC array at ATLAS Biolabs. Bioconductor R package MINIFI 522 (v1.46.0) was used to further process raw IDATs that were previously generated from iScan. 523 The quality of samples was checked by using mean detection *P*-values and only samples with 524 P-values <0.05 were kept for further processing (five samples excluded). In addition, 525 according to in-house bioinformatic QC pipelines (Glaser *et al.*, in preparation) was applied 526 (one additional case excluded). Remaining samples were normalized using quantile 527 normalization (funtion preprocessQuantile) and DNA methylation data predicted sex was 528 compared to the actual sex. Samples, where the predicted sex did not match with the actual 529 sex, were removed (four samples removed), leaving 45 samples for further analysis. DNA

530 methylation probes were quality filtered and probes with non-significant *P*-values were 531 removed (P > 0.01). Additionally, cross-reactive probes and BOWTIE2 multi-mapped probes 532 were removed, and M- and beta-values of the remaining probes were extracted ⁶⁵. 533 Differentially methylated probes between two conditions were identified using a linear 534 modeling approach as implemented in LIMMA. Generalized gene set testing on differentially 535 methylated probes was performed by applying the *gsameth* function (MISSMETHYL package

536 v1.34.0) against the REACTOME and/or HALLMARK gene sets (MSigDB v7.5).

537

538 Comparative analysis with genome-wide DNA methylation data from different cell types

539 To assess epigenetic differences between BPDCN and several cell types, we used data from 540 different sources. Raw DNA methylation data (IDAT files) from B-lymphoid cells (n = 23), 541 naïve CD4+ (n = 23), naïve CD8+ cells (n = 19), granulocytes (n = 10), monocytes (n = 24) and NK-cells (n = 20) was retrieved from GEO accession GSE184269²⁰. Data were 542 543 processed as described above with the exception that normalization was performed using 544 subset-quantile within array normalization (SWAN, MISSMETHYL) and beta-values were 545 extracted. DNA methylation profiles (beta-values) for dendritic cells (n = 6; GEO accession GSE71837⁶⁶) and hematopoietic stem cells (n = 5; GEO accession GSE63409⁶⁷) were 546 547 download using GEOquery (v2.68.0).

548 Data sets were combined (including 45 BPDCN samples), probes matching to chromosome X 549 or Y were removed, and only probes present in all studies were to remove unwanted variation 550 between the data sets (batch effects). Unwanted technical variation was removed using a two-551 stage approach (RUVm). First, a standard limma analysis was performed to identify empirical 552 control probes (ECPs). Next, the results from stage 1 were used to perform a second 553 differential DNA methylation with RUV-4 (RUVfit function provided by the MISSMETHYL 554 package) and adjusted beta-values were extracted. Region-level analysis was performed to 555 call differentially methylated regions (DMRs) using adjusted beta-values between BPDCN

and dendritic cells using DMRcate (v2.13.0) and gene set testing was performed on DMRs with fdr < 0.1 and absolute difference above 0.3 against REACTOME and HALLMARK gene sets using the *gsaregion* function (MISSMETHYL). Linkage of genes and enriched REACTOME pathways was performed for DMRs with fdr < 0.01 and absolute difference above 0.3 using *enrichPathway* (REACTOMEPA, v1.44.0, *q*-value < 0.1) and *cnetplot* (ENRICHPLOT, v1.20.0).

562

563 Comparative analysis with genome-wide DNA methylation data from acute myeloid 564 leukemia

565 Regarding epigenetic discrepancies that may aid in the distinction of borderline cases between 566 BPDCN and its predominant differential diagnosis, acute myeloid leukemia (AML), we 567 comparatively analyzed our dataset with a comprehensive, previously published AML cohort, 568 incorporating 243 samples for which genetic subtype and genome-wide DNA methylation data was available (GEO accession GSE159907⁶⁸). Data (IDAT files) was processed 569 570 (including 45 BPDCN samples) as described above using SWAN to normalize the data and 571 probes from chromosome X or Y were removed. Unwanted variation was removed using a 572 two-stage approach (RUVm). First, Illumina negative control (INCs) data for EPIC arrays 573 was extracted (411 probes) and differential DNA methylation analysis using RUV-inverse 574 with INCs as negative control features was performed. Next, the results from stage 1 were 575 used to perform a second differential DNA methylation with RUV-4 and adjusted M-values 576 were extracted for further analysis. Region-level analysis was performed to call differentially 577 methylated regions (DMRs) using adjusted M-values between BPDCN and AML using 578 DMRcate (v2.13.0) and gene set testing was performed on DMRs with fdr < 0.1 and absolute 579 difference above 0.2 against REACTOME and HALLMARK gene sets using the gsaregion 580 function (MISSMETHYL). Gene sets with P < 0.01 were considered as significantly enriched.

581 Linkage of genes and enriched REACTOME pathways was performed for DMRs with fdr <

- 582 0.01 and absolute difference above 0.2 using *enrichPathway* (q-value < 0.1) and *cnetplot*.
- 583
- 584
- 585

586 Comparative analysis with genome-wide DNA methylation data from other entities

587 Raw data files (IDAT) from AML (n = 316; GEO accession GSE159907), T-cell acute

588 lymphoblastic leukemia (t-ALL, n = 156; GEO accession GSE155339⁶⁹), and melanoma (n = 156)

589 450, TCGA project TCGA-SKCM) were downloaded and processed (including 45 BPDCN

samples) as described above using SWAN to normalize the data; probes from chromosome X

591 or Y were removed and beta-values were extracted. Additionally, beta-values for chronic

593 and merged with the processed data. Unwanted variation was removed using a 2-stage

myelomonocytic leukemia (CMML, n = 65; GEO accession GSE105420²⁴) were downloaded

approach as described in the section above ('Comparative analysis with genome-wide DNAmethylation data from different cell types').

596

592

597 Annotation of Methylated Regions

598 Probe R annotations were extracted using the package 599 ILLUMINAHUMANMETHYLATIONEPICANNO.ILM10B4.HG19 (v0.6.0). Probes annotated as 600 'Island' were classified as CpG island (CGI) probes. Probes falling into 5' UTRs or within 601 1,500 bp of the transcription start site were classified as promotor sites; sites within gene 602 bodies or 3'UTRs were defined as gene body sites.

603

604 Analysis of the tumor microenvironment by MethylCIBERSORT and 605 immunohistochemistry

606 The cellular composition of the tumor microenvironment (TME) was assessed using 607 MethylCIBERSORT as described. Beta values from raw IDATs and signature genes were deconvoluted according to immune cell populations ¹⁸. Partitioning around medoids (PAM) 608 609 was applied to identify immunologically hot versus cold immune tumors based on 610 MethylCIBERSORT calculations and to assign the optimal cluster number in the data (testing 611 from 2 to 10). Results obtained by MethylCIBERSORT were then validated through a 612 correlative immunohistochemical assessment (IHC) of the T-cell and monocyte fraction of the 613 TME. Antibodies and positivity cut-offs employed in the current study remain as described ⁶.

614

615 **DNA-methylation-based mitotic clock estimation**

To better comprehend the interaction between biological aging and molecular profiling in the light of the methylome, mitotic activity was estimated using epiCMIT. Mitotic clock was estimated on batch corrected beta-values for each sample and results were summarized per cohort ^{27, 70}.

620

621 FFPE-ATAC-seq

ATAC-sequencing on FFPE tissue sections from four typical pDC-like BPDCN patients was performed as described ⁷¹. Briefly, for nuclei isolation 20-µm-thick sections were deparaffined and underwent subsequent enzyme digestion. Then, 50.000 isolated FFPE nuclei were used in each FFPE-ATAC reaction composed of Tn5-mediated transposition and T7 in vitro transcription. FFPE-ATAC libraries were then sequenced on an Illumina NovaSeq 6000 platform at Novogene (Cambridge, UK) to a depth of at least 40 million 150-bp single-end or paired-end sequencing reads per library.

629

630 Statistical analysis

631 If not reported otherwise, statistical analysis was performed using R (v4.3.0) and p-values 632 were corrected using Benjamini-Hochberg correction. The following R packages were used: TIDYVERSE $(v2.0.0)^{51}$ for data handling and plotting; MAFTOOLS $(v2.17.0)^{72}$ to summarize, 633 634 analyze, visualize variant data; EnhancedVolcano (v1.18.0) and 635 (https://github.com/kevinblighe/EnhancedVolcano) plot volcano plots; COMPLEXHEATMAP 636 (v2.16.0) and PHEATMAP (v1.0.12) to draw heatmaps; GGPUBR (v0.6.0) for box and violin-637 plots.

Intra-tumor heterogeneity was estimated on the entropy of somatic mutation (mDITHER score) using DITHER (v1.0) ⁷³. Correlations were calculated using Spearman's rank
 correlation, if not stated differently.

641

642 Data availability

Raw data for BPDCN samples have been downloaded from European Genome-phenome archive (EGA) under the previous accession number EGAS00001006166, additional cases were deposited under accession number EGAS00001007201, respectively. EPIC array data have been deposited in Gene Expression Omnibus (GEO) under accession number GSE230487.

648

649 **Pseudonymization**

650 Processing of personal data for this study was performed pseudonymously by using a case-ID.

651 Due to pseudonymization data backtracking specific to the individual is impossible. Only the

652 initiators of the study (NG. AK, HW, JS) have access to a file that is separately stored

653 (password-protected) containing the details on pseudonymization.

654

655 Declarations

656 Ethics approval and consent to participate

657	This retrospective study was approved by the ethics committee of the University of Lübeck
658	(reference-no 18-311) and conducted in accordance with the declaration of Helsinki. Patients
659	at the Reference center for Hematopathology have provided written informed consent
660	regarding routine diagnostic and academic assessment, including genomic studies of their
661	biopsy specimen alongside transfer of their clinical data.
662	
663	Competing interests
664	The authors declare that they have no conflict of interest.
665	
666	Funding
667	This work was supported by generous funding by the Stefan Morsch Foundation through a
668	project grant (NG & HW). X.C. is supported by Swedish Research Council (2022-00658) and
669	Swedish Cancer Foundation (21 1449Pj and 22 0491).
670	
671	Author contributions
672	Study concept: NG, ACF, HM
673	Data collection: NG, AK, JS, HW, SS, PL, KN, KK, VB, HM, SS, XC, PX
674	Data analysis and creation of figures and tables: AK, NG, HW, VB, HB, NvB, MS,
675	XC, PX, FJ, HS
676	Initial Draft of manuscript: NG.
677	Critical revision and approval of final version: all authors.
678	
679	Acknowledgements
680	The authors would like to thank Tanja Oeltermann for her skilled technical assistance. AK
681	and HB acknowledge computational support from the OMICS compute cluster at the
682	University of Lübeck.

683		
684		
685		
686		
687		
688		
689		
690		
691		
692		
693		
694		
695		
696		
697	Refer	rences
698 699 700	1.	Arber DA, <i>et al.</i> The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. <i>Blood</i> 127 , 2391-2405 (2016).
701 702	2.	Chaperot L, <i>et al.</i> Identification of a leukemic counterpart of the plasmacytoid dendritic cells. <i>Blood</i> 97 , 3210-3217 (2001).
703 704 705 706 707	3.	Khoury JD, <i>et al.</i> The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. <i>Leukemia</i> 36 , 1703-1719 (2022).
707 708 709 710 711	4.	Renosi F, <i>et al.</i> Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis. <i>Blood Adv</i> 5 , 1540-1551 (2021).
712 713 714	5.	Carmona-Saez P, <i>et al.</i> Metagene projection characterizes GEN2.2 and CAL-1 as relevant human plasmacytoid dendritic cell models. <i>Bioinformatics</i> 33 , 3691-3695 (2017).
715 716 717 718	6.	Künstner A, <i>et al.</i> Integrative molecular profiling identifies two molecularly and clinically distinct subtypes of blastic plasmacytoid dendritic cell neoplasm. <i>Blood Cancer Journal</i> 12 , 101 (2022).

719		
720	7.	Laribi K, et al. Blastic plasmacytoid dendritic cell neoplasms: results of an
720	/.	international survey on 398 adult patients. <i>Blood Adv</i> 4 , 4838-4848 (2020).
722		
723	8.	Togami K, et al. Sex-biased ZRSR2 mutations in myeloid malignancies impair
724	0.	plasmacytoid dendritic cell activation and apoptosis. <i>Cancer Discov</i> , (2021).
725		
726	9.	Xiao W, et al. Plasmacytoid dendritic cell expansion defines a distinct subset of
727		RUNX1-mutated acute myeloid leukemia. Blood 137, 1377-1391 (2021).
728		
729	10.	Zalmai L, et al. Plasmacytoid dendritic cells proliferation associated with acute
730		myeloid leukemia: phenotype profile and mutation landscape. <i>Haematologica</i> Online
731		ahead of print, (2020).
732		
733	11.	Sangle NA, et al. Optimized immunohistochemical panel to differentiate myeloid
734		sarcoma from blastic plasmacytoid dendritic cell neoplasm. Mod Pathol 27, 1137-
735		1143 (2014).
736		
737	12.	Roos-Weil D, et al. Stem cell transplantation can provide durable disease control in
738		blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European
739		Group for Blood and Marrow Transplantation. Blood 121, 440-446 (2013).
740		
741	13.	Aoki T, et al. Long-term survival following autologous and allogeneic stem cell
742		transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood 125, 3559-
743		3562 (2015).
744	14	
745	14.	Pemmaraju N, <i>et al.</i> Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N
746		<i>Engl J Med</i> 380 , 1628-1637 (2019).
747 748	15.	Connor D at al DNA mothylation based aloggification of control nervous system
748 749	15.	Capper D, <i>et al.</i> DNA methylation-based classification of central nervous system
749		tumours. <i>Nature</i> 555 , 469-474 (2018).
751	16.	Koelsche C, et al. Sarcoma classification by DNA methylation profiling. Nat Commun
752	10.	12 , 498 (2021).
753		12, 490 (2021).
754	17.	Pemmaraju N, et al. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
755	17.	Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies
756		(PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern
757		Targeted Therapy Era. <i>Blood</i> 134 , 2723-2723 (2019).
758		
759	18.	Chakravarthy A, et al. Pan-cancer deconvolution of tumour composition using DNA
760		methylation. <i>Nat Commun</i> 9 , 3220 (2018).
761		
762	19.	Guidry K, et al. DNA Methylation Profiling Identifies Subgroups of Lung
763		Adenocarcinoma with Distinct Immune Cell Composition, DNA Methylation Age,
764		and Clinical Outcome. Clin Cancer Res 28, 3824-3835 (2022).
765		
766	20.	Roy R, et al. DNA methylation signatures reveal that distinct combinations of
767		transcription factors specify human immune cell epigenetic identity. Immunity 54,
768		2465-2480 e2465 (2021).
769		

770 771 772	21.	Zhang X, <i>et al.</i> DNA methylation dynamics during ex vivo differentiation and maturation of human dendritic cells. <i>Epigenetics Chromatin</i> 7 , 21 (2014).
773 774 775 776	22.	Sapienza MR, <i>et al.</i> Newly-Discovered Neural Features Expand the Pathobiological Knowledge of Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancers (Basel)</i> 13 , (2021).
777 778 779	23.	Tyner JW, <i>et al.</i> Functional genomic landscape of acute myeloid leukaemia. <i>Nature</i> 562 , 526-531 (2018).
780 781 782 783	24.	Palomo L, <i>et al.</i> DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features. <i>Epigenetics</i> 13 , 8-18 (2018).
784 785 786	25.	Liu Y, <i>et al</i> . The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. <i>Nat Genet</i> 49 , 1211-1218 (2017).
787 788 789	26.	Griffin GK, <i>et al.</i> Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin. <i>Nature</i> 618 , 834-841 (2023).
790 791 792	27.	Duran-Ferrer M, <i>et al.</i> The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome. <i>Nat Cancer</i> 1 , 1066-1081 (2020).
793 794 795	28.	Yu M, Hazelton WD, Luebeck GE, Grady WM. Epigenetic Aging: More Than Just a Clock When It Comes to Cancer. <i>Cancer Res</i> 80 , 367-374 (2020).
796 797 798	29.	Bell CG, <i>et al.</i> DNA methylation aging clocks: challenges and recommendations. <i>Genome Biol</i> 20 , 249 (2019).
799 800 801 802 803	30.	Udtha M, Lee SJ, Alam R, Coombes K, Huff V. Upregulation of c-MYC in WT1- mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors. <i>Oncogene</i> 22 , 3821-3826 (2003).
804 805 806	31.	Yin CC, <i>et al.</i> Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancers (Basel)</i> 13 , (2021).
807 808 809 810	32.	Bastidas Torres AN, <i>et al.</i> Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm. <i>Genes Chromosomes Cancer</i> 59 , 295-308 (2020).
811 812 813 814	33.	Sapienza MR, <i>et al.</i> Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. <i>Haematologica</i> 104 , 729-737 (2019).
815 816 817	34.	Sakamoto K, <i>et al.</i> Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. <i>Leukemia</i> 32 , 2590-2603 (2018).
818 819 820	35.	Wang L, <i>et al.</i> ARID1A mutation in blastic plasmacytoid dendritic cell neoplasm. <i>Haematologica</i> 102 , e470-e472 (2017).

0.2.1		
821	26	
822	36.	Suzuki K, <i>et al.</i> Recurrent MYB rearrangement in blastic plasmacytoid dendritic cell
823		neoplasm. Leukemia 31 , 1629-1633 (2017).
824	27	Continues MD of al Malassian and illing of blacking have set at day with a sill
825	37.	Sapienza MR, <i>et al.</i> Molecular profiling of blastic plasmacytoid dendritic cell
826		neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway
827		inhibition. Leukemia 28, 1606-1616 (2014).
828	20	71
829	38.	Zhou W, <i>et al.</i> DNA methylation loss in late-replicating domains is linked to mitotic
830		cell division. Nat Genet 50, 591-602 (2018).
831	20	Demons E. J. Coll of Origin DNA Methodotics Signatures And Meintained Asia
832	39.	Bormann F, <i>et al.</i> Cell-of-Origin DNA Methylation Signatures Are Maintained during
833		Colorectal Carcinogenesis. Cell Rep 23, 3407-3418 (2018).
834 825	40	Vhanlari M. et al. Done memory alongl homotopoiogic is highly provalent in blastic
835	40.	Khanlari M, <i>et al.</i> Bone marrow clonal hematopoiesis is highly prevalent in blastic
836		plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly
837 838		patients. Leukemia, (2022).
839	41.	Dencemmental E at al. Clinical and highering implications of driver mutations in
839 840	41.	Papaemmanuil E, <i>et al.</i> Clinical and biological implications of driver mutations in myelodysplastic syndromes. <i>Blood</i> 122 , 3616-3627; quiz 3699 (2013).
840 841		Inyelouyspiastic synatomes. <i>Blood</i> 122, 5010-5027, quiz 5099 (2015).
841 842	42.	Batta K, et al. Divergent clonal evolution of blastic plasmacytoid dendritic cell
842 843	42.	neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin.
843 844		Leukemia 35 , 3299-3303 (2021).
845		Leukemuu 33 , 3299-3303 (2021).
845 846	43.	Cai X, et al. Runx1 loss minimally impacts long-term hematopoietic stem cells. PLoS
840 847	45.	Car X, et al. Runx ross minimary impacts long-term hematopoletic stem cens. <i>T Los</i> One 6 , e28430 (2011).
848		<i>One</i> 0 , 6204 50 (2011).
849	44.	Wu JN, Roberts CW. ARID1A mutations in cancer: another epigenetic tumor
850		suppressor? <i>Cancer Discov</i> 3 , 35-43 (2013).
851		suppressor: Cancer Discov 5, 55-45 (2015).
852	45.	Hetzel S, et al. Acute lymphoblastic leukemia displays a distinct highly methylated
853	101	genome. Nat Cancer 3, 768-782 (2022).
854		Sonome. Nai Cancel 6, 100 102 (2022).
855	46.	McCormick SM, Heller NM. Commentary: IL-4 and IL-13 receptors and signaling.
856		<i>Cytokine</i> 75 , 38-50 (2015).
857		
858	47.	Straining R, Eighmy W. Tazemetostat: EZH2 Inhibitor. J Adv Pract Oncol 13, 158-
859		163 (2022).
860		
861	48.	Aung PP, et al. PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell
862		Neoplasm. Cancers (Basel) 11, (2019).
863		
864	49.	Witte HM, et al. Integrative genomic and transcriptomic analysis in plasmablastic
865		lymphoma identifies disruption of key regulatory pathways. <i>Blood Adv</i> , (2021).
866		
867	50.	Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor.
868		Bioinformatics 34, i884-i890 (2018).
869		
870	51.	Wickham H, et al. Welcome to the Tidyverse. The Journal of Open Source Software
871		4 , (2019).

872		
873	52.	McKenna A, et al. The Genome Analysis Toolkit: a MapReduce framework for
874	52.	analyzing next-generation DNA sequencing data. <i>Genome Res</i> 20 , 1297-1303 (2010).
875		unaryzing now generation D101 sequencing data. Genome res 2 0, 1297 1505 (2010).
876	53.	Sherry ST, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res
877	00.	29 , 308-311 (2001).
878		
879	54.	Cibulskis K, et al. Sensitive detection of somatic point mutations in impure and
880	54.	heterogeneous cancer samples. <i>Nat Biotechnol</i> 31 , 213-219 (2013).
881		neterogeneous cuncer sumples. Ivur Diotectinor 51, 215-215 (2015).
882	55.	McLaren W, et al. The Ensembl Variant Effect Predictor. Genome Biol 17, 122
883	55.	(2016).
884		(2010).
885	56.	Shyr C, Tarailo-Graovac M, Gottlieb M, Lee JJ, van Karnebeek C, Wasserman WW.
886	50.	FLAGS, frequently mutated genes in public exomes. <i>BMC Med Genomics</i> 7, 64
887		(2014).
888		(2014).
889	57.	Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr., Kinzler KW.
890	57.	Cancer genome landscapes. <i>Science</i> 339 , 1546-1558 (2013).
891		Cancer genome randscapes. Science 337, 1540-1556 (2015).
892	58.	Lawrence MS, et al. Mutational heterogeneity in cancer and the search for new
893	50.	cancer-associated genes. <i>Nature</i> 499 , 214-218 (2013).
893		cancer-associated genes. <i>Nuture</i> 477 , 214-218 (2013).
895	59.	Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21
895	59.	(2013).
897		(2013).
898	60.	Yin S, Wang X, Jia G, Xie Y. MIXnorm: normalizing RNA-seq data from formalin-
899	00.	fixed paraffin-embedded samples. <i>Bioinformatics</i> 36 , 3401-3408 (2020).
900		incer pararim-embedded samples. <i>Bioinformatics</i> 56 , 5401-5406 (2020).
901	61.	Ritchie ME, et al. limma powers differential expression analyses for RNA-sequencing
902	01.	and microarray studies. <i>Nucleic Acids Res</i> 43 , e47 (2015).
903		
904	62.	Kaspi A, Ziemann M. mitch: multi-contrast pathway enrichment for multi-omics and
905	02.	single-cell profiling data. <i>BMC Genomics</i> 21 , 447 (2020).
906		single cen pronning data. Dire Genomies 21, 117 (2020).
907	63.	Villani AC, et al. Single-cell RNA-seq reveals new types of human blood dendritic
908	00.	cells, monocytes, and progenitors. <i>Science</i> 356 , (2017).
909		cons, monocytes, and progenitors. Science bed, (2017).
910	64.	Schubert M, et al. Perturbation-response genes reveal signaling footprints in cancer
911	011	gene expression. <i>Nat Commun</i> 9 , 20 (2018).
912		gene expression iter commun 2, 20 (2010).
913	65.	Pidsley R, et al. Critical evaluation of the Illumina MethylationEPIC BeadChip
914		microarray for whole-genome DNA methylation profiling. <i>Genome Biol</i> 17 , 208
915		(2016).
916		
917	66.	Vento-Tormo R, et al. IL-4 orchestrates STAT6-mediated DNA demethylation
918		leading to dendritic cell differentiation. <i>Genome Biol</i> 17 , 4 (2016).
919		
920	67.	Jung N, Dai B, Gentles AJ, Majeti R, Feinberg AP. An LSC epigenetic signature is
921		largely mutation independent and implicates the HOXA cluster in AML pathogenesis.
922		<i>Nat Commun</i> 6 , 8489 (2015).

923		
924	68.	Giacopelli B, et al. DNA methylation epitypes highlight underlying developmental
925		and disease pathways in acute myeloid leukemia. Genome Res 31, 747-761 (2021).
926		
927	69.	Roels J, et al. Aging of preleukemic thymocytes drives CpG island hypermethylation
928		in T-cell acute lymphoblastic leukemia. Blood Cancer Discov 1, 274-289 (2020).
929		
930	70.	Horvath S. DNA methylation age of human tissues and cell types. <i>Genome Biol</i> 14,
931		R115 (2013).
932		
933	71.	Zhang H, et al. Profiling chromatin accessibility in formalin-fixed paraffin-embedded
934		samples. Genome Res 32, 150-161 (2022).
935		
936	72.	Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and
937		comprehensive analysis of somatic variants in cancer. Genome Res 28, 1747-1756
938		(2018).
939		
940	73.	Li L, Chen C, Wang X. DITHER: an algorithm for Defining IntraTumor
941		Heterogeneity based on EntRopy. Brief Bioinform 22, (2021).
942		
943		
944		
945		

946

947 **Table 1.** Baseline clinicopathological characteristics of the study group

Characteristics	BPDCN-C1	BPDCN-C2
	(n = 29)	(n = 25)
Age (yrs.; median (range))	70 (15 - 91)	74 (42 – 90)
Sex		
Female	6 (21%)	8 (32%)
Male	23 (79%)	17 (68%)
Manifestation		
Skin	20 (69%)	14 (56%)
Bone marrow	8 (28%)	8 (32%)
0 EN-sites	3 (10%)	3 (12%)
1-2 EN sites	26 (90%)	19 (76%)
> 2 EN sites	-	3 (12%)
Stage (Ann Arbor)		
I/II	2/16 (13%)	3/16 (19%)
III/IV	14/16 (87%)	13/16 (81%)
ECOG PS		
0-1	8/10 (80%)	3/11 (27%)
≥2	2/10 (20%)	8/11 (73%)
B-symptoms		
No	6/14 (43%)	4/15 (27%)
Yes	8/14 (57%)	11/15 (73%)
Immunohistochemistry		
BPDCN-specific	29/29 (100%)	25/25 (100%)
CD56 ⁺	29/29 (100%)	25/25 (100%)

CD123 ⁺	29/29 (100%)	25/25 (100%)
TCL1	27/28 (96%)	17/23 (74%)
Immature lineage marker	21/29 (72%)	19/24 (79%)
CD34	1/29 (3%)	4/24 (17%)
$\mathrm{T}\mathrm{d}\mathrm{T}^+$	21/29 (72%)	16/23 (70%)
T-lineage markers	28/29 (96%)	24/25 (96%)
CD2 ⁺	5/22 (23%)	7/16 (44%)
$CD3^+$	4/26 (15%)	5/23 (22%)
$CD4^+$	28/29 (96%)	23/25 (92%)
B-lineage marker CD79A ⁺	23/28 (82%)	20/23 (87%)
Myeloid-lineage markers	24/26 (92%)	21/23 (91%)
CD33 ⁺	24/26 (92%)	20/23 (87%)
CD117 ⁺	2/26 (8%)	9/23 (39%)
MPO^+	1*/28 (4%)	4*/23 (17%)
Ki-67 (median, range)	60% (30 - 90%)	50% (25 - 90%)
Abbreviations: BPDCN, blastic plasma	cytoid dendritic cell neoplasm;	ECOG, Eastern Cooperative
Oncology Group; EN, extranodal; MPC), myeloperoxidase; yrs, years.	*cases with concurrent other
myeloid neoplasia (CMML or AML).		

948

949

950

951

952

953

961

954 **Figure Legends:**

955 Figure 1. Epigenetic profiles of BPDCN and sorted hematopoietic cell populations.

a First and second principal components of the 10,000 most variable DNA methylation sites

in BPDCN (C1 and C2) and various hematopoietic cell types (B = B lymphocytes, Granulo =

958 granulocytes, HSC = hematopoietic stem cells, iDC = immature dendritic cells, mDC =

959 mature dendritic cells, Mono = monocytes, NK = natural killer cells; ellipses show 95%

960 confidence intervals of multivariate normal distribution). **b** Average genome-wide DNA

962 and C2. Individual estimates are shown as dots and cell type-specific distributions are shown

methylation level (beta values) of BPDCN and various cell types and of BPDCN cluster C1

963 as box- and violin-plots; significant differences against BPDCN were assessed by unpaired

905 as box- and violin-plots, significant differences against BPDCN were assessed by unparted

964 Wilcoxon test and significant levels are indicated by asterisks (* = p < 0.05, ** = p < 0.01,

965 and *** = p < 0.001). c Enrichment analysis of differentially methylated regions (DMRs)

between BPDCN and dendritic cells (harmonic mean of the individual CpG FDRs < 0.01,
absolute difference above 0.3) against HALLMARK and REACTOME gene sets. Only
significant gene sets are shown (FDR < 0.1). d Network enrichment against REACTOME for
DMRs (as in c); fold changes of DMRs (BPDCN vs DC) are color-scaled (red: higher DNA
methylation in BPDCN; blue: higher DNA methylation in DC) and gene sets are denoted by
light-brown nodes.

972

973 Figure 2. BPDCN DNA methylation in comparison to AML, CMML, t-ALL and 974 melanoma.

975 **a** Visualization of the first and second principal components of the 10,000 most variable DNA 976 methylation sites (ellipses show 95% confidence intervals of multivariate normal 977 distribution). b Partial-least squares discriminant analysis (PLS-DA) of adjusted beta values. c 978 First and second principal components of the comparison between BPDCN and AML 979 (*RUNX1* wild-type and mutated samples highlighted differently). The four BPDCN cases 980 falling inside the 95% confidence interval of the AML data are labeled. (d-j) a prototypical 981 borderline case with both typical BPDCN as well as AML with pDC-like features; d 982 Morphology of the neoplastic infiltrate within the lymph node resembles acute leukemia with 983 polymorphic blast-like cells of variable size (H&E, 40x). e Uniform expression of CD123 984 initially led to the inclusion of BPDCN into the differential diagnosis (CD123, 40x). **f** Further 985 immunophenotypic work-up revealed several atypical features, reminiscent of AML with 986 partial pDC phenotype, including variable expression of CD33 in a significant fraction of the 987 malignant infiltrate (CD33, 40x), yet only partial expression of CD56 (g; CD56, 200x) and 988 CD117 (h; CD117, 200x). i The bi-phenotypic character of the infiltrate is further underlined 989 by a strong CD34 expression of a minor fraction of the blast-like cells alongside the vascular 990 structures, resembling the pDC-like AML phenotype component, whereas the majority of 991 blasts resemble phenotypically characteristic BPDCN cells. j Two-dimensional density plots

992 of average CpG site DNA methylation in BPDCN vs AML, CMML, t-ALL and melanoma 993 (low density: orchid; high density: yellow/orange). k Average genome-wide DNA 994 methylation level (beta values) of BPDCN, AML, CMML, t-ALL and melanoma; for BPDCN 995 subcluster estimates are shown as well. I DNA-methylation-based mitotic clock (epiCMIT) 996 estimates for each entity and BPDCN subtypes. m Network enrichment against REACTOME 997 for DMRs between BPDCN and AML; fold changes are color-scaled (red: higher DNA 998 methylation in BPDCN; blue: higher DNA methylation in AML) and gene sets are denoted by 999 light-brown nodes. **n** Pathway enrichment against REACTOME gene sets of gene-associated 1000 CpGs between BPDCN (blue) and AML (orange). o Pathway enrichment against 1001 REACTOME gene sets of promotor-associated CpGs between BPDCN (blue) and AML 1002 (orange). 1003 If not stated differently, differences between BPDCN and the 4 other entities were assessed

by unpaired Wilcoxon test and significant levels are indicated by asterisks (* = p < 0.05, ** = p < 0.01, and *** = p < 0.001).

1006

1007

1008 Figure 3. DNA methylation of tumor suppressor genes in BPDCN, AML and CMML.

1009 a Average promoter DNA methylation (beta values) of tumor suppressor genes in BPDCN,

1010 AML and CMML. b Average gene body DNA methylation (beta values) of tumor suppressor

1011 genes in BPDCN, AML and CMML. c Average promoter and gene body DNA methylation in

- 1012 selected tumor suppressor genes (for a complete representation of significantly divergent
- 1013 TSGs see **Supplementary Figure 2**).

1014 Differences between BPDCN and the AML/CMML were assessed by unpaired Wilcoxon test

1015 and significant levels are indicated by asterisks (* = p < 0.05, ** = p < 0.01, and *** = p < 0.01

1016 0.001).

1018 Figure 4. Differential DNA methylation, expression and mutation patterns in BPDCN

1019 subtypes C1 and C2.

1020 **a** Top part of the heatmap shows mutational patterns of 14 genes previously identified as significantly enriched between the two clusters ⁶. The bottom part shows scaled beta values 1021 1022 (DNA methylation levels) of differentially methylated CpG sites (p < 0.0001). **b** Volcano plot 1023 of beta values showing log₂ fold-changes and p-values with gene annotations for significantly 1024 different CpGs (p < 0.0001). c Gene set enrichment analysis results of DNA methylation data 1025 against REACTOME gene sets (p < 0.05). **d** Volcano plot of expression profiles showing \log_2 1026 fold-changes and p-values with gene annotations for significant differentially expressed tumor 1027 suppressors genes, oncogenes and genes involved in cell adhesion/cell cycle (p < 0.0001). e 1028 Gene set enrichment analysis of RNA-seq data against REACTOME gene sets ($p_{adj} < 0.001$, 1029 absolute enrichment > 0.3). f Transcription factors with significantly different inferred 1030 activity (p < 0.05) in C1 (light blue) and C2 (dark blue). g Pathway activities in C1 (light 1031 blue) and C2 (dark blue) with significantly different pathway activities shown in red font (p < p1032 0.05). h,i FFPE-ATAC-seq estimates of chromatin accessibility for CDK6 and STAT5A for 1033 four BPDCN cases belonging to subcluster C1. CDK6 is located on the minus strand and 1034 STAT5B on the plus strand, respectively.

1035

Figure 5. Tumor immune composition by MethylCIBERSORT identifies clusters of divergent immunogenicity.

a DNA methylation data were deconvoluted according to immune cell populations
(MethylCIBERSORT). This revealed two different types of BPDCN (Treg and CD14 driven;
named IC1 and IC2, respectively) presenting with significantly differing immune cell subsets
in regard to the markers CD14 (monocytes/macrophages), CD19 (B-cells), CD4 (T-helper
cells) as well as fibroblasts, NK-cells and T-regulatory cells (T-regs). b – e A borderline
BPDCN/AML pDC-like case analyzed by MethylCIBERSORT and a comparative

1044 immunohistochemical assessment of the tumor microenvironment is presented. b H&E 1045 staining reveals a cutaneous infiltrate covered by an intact epidermis. c Giemsa staining 1046 reveals small blastoid cells with partly roundish occasionally monocytoid nuclei, small 1047 nucleoli and weakly basophilic cytoplasm with increased mitotic activity. d Staining for 1048 myeloid peroxidase reveals expected negativity in the malignant infiltrate alongside a few 1049 positive, tumor-infiltrating myeloid cells. e However, CD14-Expression highlights both a 1050 typical negative BPDCN population, as well as a relevant monocytoid population, including 1051 few tumor-infiltrating monocytes alongside a larger subgroup of malignant cells. **f** Oncoplot 1052 displays mutational patterns of 9 genes that were found to be more differentially mutated 1053 between IC1 and IC2. Additionally, the heatmap illustrates TME cell proportions for each 1054 individual sample. g, h Progression-free (PFS) and Overall survival (OS) analysis for patients 1055 with available clinical follow-up according to IC1 vs IC2 identifies a significant inferior 1056 prognostic impact for the IC1 subtype regarding PFS accompanied by a trend towards inferior 1057 OS.

1058


1059


Figure 6. Impact of significant driver mutations and DNA methylation status of epigenetic regulators on proliferative history and global CGI DNA methylation.


1062 (a) Oncoplot displaying putative driver genes inferred by MUTSIGCV analysis in addition to 1063 tumor mutational burden (TMB; upper bar plot), $-log_{10}$ p-values (left bars) and the number of 1064 samples harboring mutations in a given gene (right bar). In total 6.065 bioinformatically 1065 deleterious mutations, in 3,970 genes were observed. Of these indels and SNVs, 4,999 were 1066 missense (82.4%), 321 nonsense (5.3%), 12 non-stop (0.2%) and 487 indel mutations (8.0%). 1067 Mutation types are color-coded, and covariates are shown below for each sample (covariate 1068 'Other' refers to samples with tissue affected other than skin or bone marrow). (b) Analysis of 1069 which significant mutational driver alterations may confer a higher or lower proliferative


1070	capacity to BPDCN cells. Statistically significant associations are delineated in red and blue,
1071	respectively. (c) Comparative analysis regarding proliferative capacity in selected genes'
1072	mutant and wild-type status. (d) A heatmap depicting the DNA methylation status of gene
1073	promoter regions across a set of preselected epigenetic regulators associated directly and
1074	indirectly with global DNA methylation, as described ⁴⁵ . Average global DNA methylation
1075	and CpG islands (CGI) are estimated per patient.
1076 1077	
1078	
1079	
1080	
1081	
1082	
1083	
1084	
1085	
1086	
1087	Supplementary Figures:
1088	Supplementary Figure 1: Deconvolution of bulk RNA-seq from the extended cohort of
1089	BPDCN patients.
1090	
1091	Supplementary Figure 2: Complete representation of promotor and gene body DNA
1092	methylation of TSGs (according to Vogelstein et al.).
1093	
1094	Supplementary Figure 3: Mutational landscape according to BPDCN C1 vs C2. a
1095	significantly differentially mutated genes between C1 and C2. b TMB according to C1 vs C2
1096	


1097	Supplementary Figure 4: Correlating the results from our MethylCIBERSORT approach
1098	with the genomic landscape
1099	
1100	Supplementary Figure 5: Mutational, epigenetic and immunohistochemical properties
1101	according to ICs
1102	
1103	Supplementary Figure 6: Quantitative estimation of tumor-infiltrating T-cells by a IHC and
1104	b MethylCIBERSORT
1105	
1106	Supplementary Figure 7 : Unsupervised clustering of most variable methylated probes (n =
1107	5,600) a. Heatmap b. TMB according to MethCs
1108	
1109	
1110	
1111	
1112	
1113	Supplementary Tables
1114	Supplementary Table 1: Variants
1115	Supplementary Table 2: MutSigCV
1116	Supplementary Table 3: Clinical data
1117	Supplementary Table 4: beta values for differentially methylated probes in the BPDCN
1118	cohort.
1119	Supplementary Table 5: a) Correlation between DNA methylation and gene expression
1120	for selected Genes (TSGs and oncogenes). b) Correlation between DNA methylation and
1121	gene expression for the entire transcriptome.














epiCMIT Mutated vs Wild type

а